IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
BioWa 2008 POTELLIGENT
technology
Global Alliance for TB
Drug Development
Terms of Agreement
BioWa signed a deal with Novartis relating
to its patented POTELLIGENT technology.
Novartis will have access to the
POTELLIGENT platform for the R&D,
manufacture and commercialization of
antibody-dependent cellular cytotoxicity
(ADCC) enhanced antibodies for an
undisclosed number of targets. Novartis
will pay BioWa license fees and
development milestone payments. BioWa
will receive royalties on any products
developed by Novartis. BioWa’s
POTELLIGENT technology comprises an
FUT8 knockout CHO cell line that enables
the production of fucose-deficient
monoclonal antibodies.
2008 TB The Novartis Institute for Tropical Diseases
(NITD) and the Global Alliance for TB Drug
Development are collaborating on a 5-year
program to develop agents for the
treatment of tuberculosis (TB), including
drug-resistant TB. The NITD and the
Global Alliance for TB Drug Development
will share information on new and ongoing
TB drug discovery projects. The deal
allows for future collaborative
development of antibiotic compounds.
Discovery stage research is under way.
The NITD is a private-public partnership
between Novartis and the Singapore
Economic Development Board.
MorphoSys 2007 Drug discovery and
development
© 2009 IMS Health In cor po rated or its af fil i ates Page 131
10-year comprehensive strategic alliance
to discover and develop therapeutic
antibodies against a wide range of
diseases, using MorphoSys’ HuCAL-based
drug discovery platform. The two
companies will combine their R&D
capabilities to establish a pipeline of
biopharmaceuticals and will share rights to
co-developed products in specific
territories.